Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

Withdrawn before enrolling · Phase 1/Phase 2

Conditions studied: HER2-positive Breast Cancer

In brief

The purpose of the study is to see if a new group of imaging tests can help identify response to stage IV HER2+ breast cancer before treatment.

Key facts

Study ID

NCT04273555

Run by

University of Alabama at Birmingham

People needed

0

Starts

2026-03-01

Expected to finish

2028-06-30

Last updated by the study team

2026-07-01

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients must be ≥ 18 years old and ≤ 75 years old
• Patients with HER2+ metastatic breast cancer
• HER2-positive breast cancer prospectively determined on the primary tumor by a local pathology laboratory and defined as immunohistochemistry (IHC) score of 3+ and/or positive by in situ hybridization (ISH) (defined by ISH ratio of ≥ 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies). Only one positive result is required for eligibility
• Estrogen/progesterone receptor positive OR negative disease allowed
• Patients must have measurable disease in one metastatic lesion per RECIST v 1.1
• Stage IV HER2+ breast cancer patients eligible for a new therapeutic regimen that includes HER2-targeted treatment who are naïve to that regimen
• Estimated life expectancy of greater than six months

You may not qualify if…

• Children, less than 18 years of age, will be excluded from this study
• Metastatic breast cancer patients who are HER2 positive and have already started their current HER2-targeted therapy regimen for metastatic disease
• Patients who have not recovered from grade 2 or higher toxicities of prior therapy to the point that they would be appropriate for re-dosing will be ineligible for study treatment
• Patient is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the screening visit through 7 months after the last dose of study treatment
• Patient is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active infection that requires systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining informed consent).
• Patients found to have constitutionally present non-magnetic resonance (MR) compatible ferromagnetic materials
• Unable to lie still on the imaging table for one (1) hour
• Inability to receive gadolinium-based contrast agent
• Patients for whom a PET/MRI is technically not feasible (e.g. breast volume, obesity, > body mass index (BMI) 36)

Where it is running

• The University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.